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tp://dx.doi.org/10.1016/j.gendis.2
52-3042/Copyright ª 2015, ChongqAbstract We devote this short piece to highlight one recent article published in Cell Stem
Cell, reporting the correction of large chromosomal inversions of the factor VIII (F8) gene in
cells from Hemophilia A patients using the CRISPR-Cas9 technology, one of the first attempts
to edit large segments of chromosomes in patient cells using such methodology. The corrected
cells were found free of off-target mutations and producing functional factor VIII in hemophilia
mouse model. This work heralds another major advance in bringing CRISPR closer to the ther-
apeutic reality.
Copyright ª 2015, Chongqing Medical University. Production and hosting by Elsevier B.V. All
rights reserved.Precision genome editing using the CRISPR (Clustered Re-
gions of Interspersed Palindromic Repeats) endonuclease
technology has started to come of age. With its ever-
improving specificity, the initial clinical safety concerns
regarding off-target genetic mutations have been tapering
off. Medical science has never been so close to realizing the
dream of correcting gene mutations, the culprits of many
inheritable diseases, with pinpoint precision. The advent of
CRISPR technology greatly enhanced the feasibility of
finding cures for untreatable genetic diseases in the not-so-
distant future.1 Added to the parade of successful proof-of-
principle experiments is a recent Cell Stem Cell article by
Park, et al, reporting the correction of large chromosomal
inversions in the factor VIII (F8) gene in cells from Hemo-
philia A patients using the CRISPR-Cas9 technology.2 In this
study, the authors first generated induced pluripotent stem
cell (iPSC) clones from the patients’ somatic cells and
subsequently corrected the chromosomal inversions of the
F8 gene, one of the first attempts to edit large segments of
chromosomes in patient cells using the CRISPR-Cas9ity of Chongqing Medical
015.08.005
ing Medical University. Productionmethodology. The authors did not detect any off-target
mutations among the chromosomally corrected iPSC
clones using whole-genome and targeted deep sequencing,
suggesting that the risk of unintended gene alterations was
kept minimal. Endothelial cells (a major source of plasma
coagulation factor VIII in normal subjects) were derived
from the corrected iPSC clones. By transplanting these
corrected endothelial cells into a mouse model of lethal
hemophilia, the authors were able to demonstrate in vivo
restoration of the plasma factor VIII activity, which was
correlated with a shortened bleeding time, as well as pro-
longed survival. However, it remains unknown how long
these corrected endothelial cells last in the animals after
injection, and it is unclear whether these cells actually
engraft in the mouse vascular vessels so that the cure can
be considered permanent. In order to sustain long-term
efficacy, the corrected cells must be engrafted into the
patient’s tissues or organs, which is difficult to achieve due
to the extremely low engrafting efficiency of certain types
of cells, including those of the endothelial lineage. Despite
these hurdles, this newly reported benchmark success
represents another major step forward in bringing this
CRISPR-tale closer to a bedside reality.and hosting by Elsevier B.V. All rights reserved.
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